Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $20.2M | $27.1M | $32.1M | $41.0M | $49.1M | $53.9M | $50.2M | $56.9M |
| Revenue growth | — | — | — | 33.7% | 18.7% | 27.8% | 19.7% | 9.7% | -6.9% | 13.5% |
| Operating income | -$10.3M | -$6.81M | -$1.35M | $270K | -$1.92M | $366K | $607K | -$5.26M | -$7.36M | $4.55M |
| Operating margin | — | — | -6.7% | 1.0% | -6.0% | 0.9% | 1.2% | -9.8% | -14.7% | 8.0% |
| Net income | -$10.4M | -$6.88M | -$1.48M | $128K | -$2.09M | $362K | $548K | -$5.33M | -$7.28M | $4.70M |
| Net margin | — | — | -7.3% | 0.5% | -6.5% | 0.9% | 1.1% | -9.9% | -14.5% | 8.3% |
| EPS (diluted) | -$1.20 | -$0.64 | -$0.13 | $0.01 | -$0.18 | $0.02 | $0.04 | -$0.39 | -$0.54 | $0.33 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.41M | -$2.84M | -$1.23M | $1.86M | $2.90M | -$1.68M | $6.50M | $3.97M | -$6.14M | $7.39M |
| Capital expenditures | $322K | $766K | $1.23M | $834K | $2.22M | $3.28M | $2.38M | $2.87M | $836K | $389K |
| Free cash flow | -$6.73M | -$3.61M | -$2.46M | $1.03M | $685K | -$4.96M | $4.11M | $1.10M | -$6.97M | $7.00M |
| Share buybacks | — | — | — | — | — | — | $0.00 | $74.0K | $634K | $0.00 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.58M | $3.44M | $1.01M | $3.24M | $8.34M | $4.69M | $9.01M | $10.1M | $2.62M | $9.79M |
| Total assets | $5.78M | $8.01M | $8.08M | $11.3M | $20.8M | $27.6M | $35.4M | $34.3M | $26.1M | $32.3M |
| Total liabilities | $5.54M | $7.61M | $8.07M | $9.03M | $15.7M | $20.2M | $26.3M | $29.7M | $28.0M | $28.6M |
| Shareholders' equity | $238K | $400K | $3.00K | $2.14M | $5.10M | $7.43M | $9.10M | $4.64M | -$1.90M | $3.77M |
| Retained earnings | -$62.5M | -$69.3M | -$70.8M | -$70.7M | -$72.9M | -$72.5M | -$72.0M | -$77.3M | -$84.6M | -$79.9M |
| Shares (wtd avg diluted) | 8.70M | 11.0M | 11.0M | 14.1M | 11.8M | 14.6M | 14.2M | 13.5M | 13.5M | 14.3M |
Every figure is extracted from CHAMPIONS ONCOLOGY, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.